Antibody drug conjugates (ADCs) at Sterling

13th Apr 2022

With the transformative potential of antibody drug conjugates in treating cancer and other indications, you’ve developed a promising new concept or ADC but, you’re not only faced with selecting the right antibody, linker, toxin, and conjugation chemistry… you must do all of this while balancing scalability, quality, and safety. Mastering this balancing act requires a partner who delivers extensive bioconjugation expertise and close scientific collaboration to set your ADC up for long-term success. Sterling is that partner.

With over a decade’s experience in bioconjugation, our experts work in close partnership with our clients to deliver a uniquely flexible and collaborative service. We have supported more than 60 clients worldwide from our Deeside, Wales facility, which has been custom built for containment, to accommodate highly potent bioconjugates and cytotoxic materials, whilst prioritising the safety of our people and our planet.

Over the last ten years, we have developed relationships with customers and suppliers, many of whom we still partner with to this day. In addition to our purpose-built facilities and experience, our flexible approach and specialised teams position us as an ideal partner for even the most complex ADC project requirements.

At Sterling, we deliver comprehensive ADC services, spanning the ADC lifecycle, including discovery, proof of concept, analytical services, process development and GMP manufacturing. All of this is supported by our team of experienced scientists who are committed to providing the quality, service, and collaboration that aligns with our partnership approach. Our teams are experienced in biochemistry, bioassays, microbiology and analytical testing, meaning we can support a range of ADC analysis.

Our mass spectrometry service, which can be offered as an integrated or stand-alone service, provides you with the data that will empower you to develop cutting edge biotherapeutics and APIs. As part of the integrated global Sterling network, we offer linker and payload synthesis at our Cary, North Carolina facility and specialist high potency facility in Germantown, Wisconsin in the US; supporting your ADC from pre-clinical to GMP manufacture.

At Sterling, we are more than a traditional contract development and manufacturing organisation. We are a partnership, development and manufacturing organisation, or PDMO®; committed to achieving true scientific collaboration.

We continue to actively invest in our Deeside site, and our people, to ensure we are continuously adding the expertise, capacity and capabilities required to maintain our flexible, collaborative partnership offering and support our clients throughout the ADC lifecycle.

Are you ready to work with a responsive team that is wholly dedicated to advancing your transformative ADC?

Sterling. Service. Passion. Science.


Related content


Sterling expands ADC capabilities and laboratory capacity at Deeside


Sterling appoints Stewart Mitchell as site head for its ADC facility


Antibody drug conjugates (ADC): The magic bullets